GCP
CNST

GSA Capital Partners’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

GSA Capital Partners’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-36,566
Closed -$1.05M – 1648
2020
Q4 		$1.05M Buy
+36,566
New +$920K 0.17% 124
2020
Q1 		– Sell
-9,458
Closed -$446K – 1738
2019
Q4 		$446K Buy
+9,458
New +$273K 0.05% 735

Other funds holding CNST

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

GSA Capital Partners's CNST Position: Q1 2021 in Review

GSA Capital Partners sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q1 2021, closing a stake of 36,566 shares — an estimated $1.05M sold.

GSA Capital Partners first reported a position in CNST in Q4 2019 and held it in 2 quarters. The position peaked at $1.05M in Q4 2020. 131 funds tracked by Wall St. Rank hold CNST as of Q1 2021.

  • GSA Capital Partners reported no remaining Constellation Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • GSA Capital Partners sold 36,566 Constellation Pharmaceuticals, Inc. shares in Q1 2021, an estimated $1.05M.
  • GSA Capital Partners first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
  • GSA Capital Partners's Constellation Pharmaceuticals, Inc. position peaked at $1.05M in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q1 2021.

Based on GSA Capital Partners's 13F filing for Q1 2021, filed 10 May 2021.